GGrantIndex
← Search

SWOG Network Group Operations Center of the NCTN

$1,989,632U10FY2025CANIH

Oregon Health & Science University, Portland OR

Investigators

Charles D. Blankecontact

Linked publications, trials & patents

Trial NCT07638722Trial NCT07636564Trial NCT07615049Trial NCT07578116Trial NCT07437950Trial NCT07393555Trial NCT07383441Trial NCT07220187Trial NCT07061964Trial NCT07042295Trial NCT06998940Trial NCT06769126Trial NCT06672146Trial NCT06616584Trial NCT06498635Trial NCT06470243Trial NCT06337318Trial NCT06210750Trial NCT06203600Trial NCT06116682Trial NCT06058377Trial NCT06031688Trial NCT06022939Trial NCT05929768Trial NCT05890352Trial NCT05806515Trial NCT05642572Trial NCT05633615Trial NCT05633602Trial NCT05564390Trial NCT05561387Trial NCT05554406Trial NCT05554380Trial NCT05411081Trial NCT05364645Trial NCT05308446Trial NCT05136196Trial NCT05096663Trial NCT05058651Trial NCT05040360Trial NCT04989283Trial NCT04871529Trial NCT04840602Trial NCT04799275Trial NCT04647916Trial NCT04625647Trial NCT04579224Trial NCT04548752Trial NCT04511013Trial NCT04334941Trial NCT04315324Trial NCT04310020Trial NCT04269902Trial NCT04268550Trial NCT04267913Trial NCT04214262Trial NCT04205968Trial NCT04173507Trial NCT04155034Trial NCT04071457Trial NCT03971474Trial NCT03907488Trial NCT03845296Trial NCT03775265Trial NCT03768414Trial NCT03698019Trial NCT03694002Trial NCT03678025Trial NCT03654768Trial NCT03598257Trial NCT03499808Trial NCT03377556Trial NCT03373760Trial NCT03365882Trial NCT03269669Trial NCT03228537Trial NCT03092674Trial NCT03091660Trial NCT03033576Trial NCT02965716Trial NCT02965378Trial NCT02954874Trial NCT02926638Trial NCT02890355Trial NCT02844816Trial NCT02834013Trial NCT02785952Trial NCT02785939Trial NCT02775851Trial NCT02766335Trial NCT02761057Trial NCT02642042Trial NCT02595905Trial NCT02562716Trial NCT02506153Trial NCT02438722Trial NCT02196181Trial NCT02177695Trial NCT02164916Trial NCT02154490

Abstract

SWOG's overarching goal is to conduct high-impact cancer trials with results meaningful to our investigators and patients. In a recent analysis, SWOG investigators examined how our treatment trials have benefited patients with cancer in the general population over the course of its 60-year history (Unger, JAMA Oncol 2017). Three and one-third million life-years were gained in the population of US patients with cancer through 2015, at an investment dollar cost on the part of the NCI of $125 per life-year gained. This clearly illustrates how the NCI's investment in its cancer cooperative group research program has provided exceptional value and benefit to the American public. We will continue to develop and conduct trials aimed at making a significant, cost-effective difference for those affected by cancer.

View original record on NIH RePORTER →